ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2019.7594 ETM-0-0-7594 Articles Resveratrol protects against asthma-induced airway inflammation and remodeling by inhibiting the HMGB1/TLR4/NF-κB pathway JiangHuanhuan DuanJunyan XuKaihong ZhangWenbo Department of Pediatrics, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China Correspondence to: Dr Wenbo Zhang, Department of Pediatrics, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, 29 Xinglong Lane, Changzhou, Jiangsu 213000, P.R. China, E-mail: rpsf14@163.com 07 2019 20 05 2019 18 1 459 466 13082018 29032019 Copyright: © Jiang et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The aim of the present study was to explore the protective role of resveratrol (RES) in asthma-induced airway inflammation and remodeling, as well as its underlying mechanism. An asthma rat model was induced by ovalbumin (OVA) treatment. Rats were randomly assigned into sham, asthma, 10 µmol/l RES and 50 µmol/l RES groups. The amount of inflammatory cells in rat bronchoalveolar lavage fluid (BALF) was detected. Pathological lesions in lung tissues were accessed by hematoxylin and eosin (H&E), and Masson's trichrome staining. Levels of inflammatory factors in lung homogenate were detected via ELISA. The blood serum of asthmatic and healthy children was also collected for analysis. Reverse transcription-quantitative polymerase chain reaction was performed to detect high mobility group box 1 (HMGB1), Τoll-like receptor 4 (TLR4), myeloid differentiation primary response gene 88 (MyD88) and NF-κB expression in asthmatic and healthy children, as well as rats of the different groups. H&E staining demonstrated that multiple inflammatory cell infiltration into the rat airway epithelium of the asthma group occurred whilst the 50 µmol/l RES group displayed alleviated pathological lesions. Masson staining indicated that there was an increased airway collagen deposition area in the asthma and 10 µmol/l RES groups compared with the 50 µmol/l RES group. The number of inflammatory cells in BALF extracted from rats of the asthma and 10 µmol/l RES groups was higher compared with the 50 µmol/l RES group. Treatment with 50 µmol/l RES significantly decreased the thicknesses of the airway wall and smooth muscle. ELISA results illustrated that interleukin (IL)-1, IL-10 and tumor necrosis factor-α (TNF-α) levels were elevated, whereas IL-12 level was reduced in lung tissues of the asthma and 10 µmol/l RES groups whilst the 50 µmol/l RES group demonstrated the opposite trend. HMGB1, TLR4, MyD88 and NF-κB mRNA levels were remarkably elevated in rats of the asthma and 10 µmol/l RES groups compared with the 50 µmol/l RES group. Serum levels of IL-1, IL-10 and TNF-α were elevated, whereas IL-12 was reduced in asthmatic children compared with healthy children. The present results demonstrated that a large dose of RES alleviated asthma-induced airway inflammation and airway remodeling by inhibiting the release of inflammatory cytokines via the HMGB1/TLR4/NF-κB pathway.

 asthma inflammatory response high mobility group box 1/Τoll-like receptor 4/NF-κB resveratrol Introduction

Asthma is a common chronic respiratory disease in children. Its main pathological features are airway inflammation and airway remodeling. Eosinophils, neutrophils and other inflammatory cells participate in asthma-induced airway remodeling (1–3). As a chronic inflammatory disease, asthma may progress to irreversible airway remodeling without the appropriate treatment (4). Research has identified that asthma pathogenesis involves multiple mechanisms, including genetic mechanisms, the immune response, chronic airway inflammation, airway hyper responsiveness, airway neuromodulation disorders and neural signaling pathway (5–7). The immune response is the leading pathogenic factor.

High mobility group box 1 (HMGB1) is a highly conserved nuclear protein that is released by mononuclear cells, macrophages and other immune cells following stimulation by lipopolysaccharide, tumor necrosis factor-α (TNF-α) or interleukin (IL)-1. HMGB1 is also passively released from damaged and necrotic tissue cells to further promote the secretion of a number of inflammatory factors. As a vital endogenous pro-inflammatory factor and inflammatory mediator, HMGB1 participates in the pathological processes of sepsis, pneumonia, arthritis and other diseases (8,9). Extracellular HMGB1 promotes cytokine release via the mitogen-activated protein kinase (MAPK), ERK1/2 and NF-κB pathways (10). HMGB1 also activates Τoll-like receptor (TLR) 2 and TLR4, which in turn leads to a downstream inflammatory response via targeting myeloid differentiation primary response gene 88 (MyD88) and NF-κB (11). It has been demonstrated that TLR4 is an essential receptor in HMGB1-induced inflammation (12). HMGB1 exerts its pro-inflammatory role via binding to TLR4 leading to release of inflammatory cytokines such as IL-β, IL-10, IL-12 and TNFα (13,14). The present study hypothesized that the HMGB1/TLR4/NF-κB pathway may be of great significance in the pathogenesis of asthma.

In recent years, resveratrol (RES) has attracted research focus due to its low toxicity and wide range of action. Beneficial effects of RES have been demonstrated in pulmonary fibrosis, chronic obstructive pulmonary disease, pulmonary hypertension and other lung diseases (15–17). RES can effectively inhibit eosinophil activation and degranulation (18), and alleviate airway inflammation and airway hyper-responsiveness in an acute asthma model (19). In addition, RES regulates the differentiation of type 1 T helper (Th1)/Th2 cells through Tbet/GATA binding protein 3 pathway, suggesting that RES may have a role in protecting against bronchial asthma (20). However, the specific mechanisms of RES in regards to asthma remains not fully understood. The present study first constructed an asthma rat model. Following intervention with different doses of RES, the alterations in rat airway remodeling and the HMGB1/TLR4/NF-κB pathway were observed. These findings provided a theoretical basis for improving clinical asthma outcomes in children.

 Materials and methods <sec> <title>Animal procedures

A total of 40 male Sprague Dawley rats (age, 4 weeks; weight, 80±15 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed at 24±3°C and humidity of 40–60% on a 12-h light/dark cycle (lights on at 06:00 am). The rats were provided food and water ad libitum. Rats were acclimated for 1 week and subsequently randomly assigned into the sham, asthma, 10 µmol/l RES or 50 µmol/l RES groups (n=10).

 Asthma rat model construction

A total of 0.2 ml of mixed antigen [2 mg ovalbumin (OVA) + 40 mg aluminum hydroxide] solution (Sigma-Aldrich; Merck KGaA) was intraperitoneally injected into rats of the asthma group, 10 µmol/l RES (Sigma-Aldrich; Merck KGaA) group and 50 µmol/l RES group on day 1, 8 and 15, respectively. Rats in the sham group received intraperitoneal injection of 0.2 ml of saline. On day 22, rats in the asthma group, 10 µmol/l RES group and 50 µmol/l RES group received atomization inhalation of 1% OVA to induce the asthma model. For the RES group rats, 30 min before inhalation of OVA, 0.2 ml of either 10 µmol/l or 50 µmol/l RES was injected intraperitoneally into rats. Rats in the sham group and asthma group were injected with 0.2 ml of saline. The experiment lasted until day 35.

 Bronchoalveolar lavage fluid (BALF) sample collection

Rats were anesthetized with 1% sodium pentobarbital (40 mg/kg) intraperitoneally prior to collection of BALF. In brief, 1 ml of saline was injected into rats then repeat suction was performed three times. BALF was recycled and centrifuged at 400 × g for 15 min at 4°C. A sample was considered as suitable for experimentation when the recycled amount was >0.8 ml. Cell counting was performed within 1 h. Cell sedimentation was resuspended with PBS solution, then 10 µl was used for measurement of total cell number. Then 0.1 ml was used for cell pellets smear. The cell pellets smear was fixed and stained with Wright's staining. Cells were differential counted in three visual field and the values were averaged as previously described in the literature (19).

 Hematoxylin and eosin (H&E) staining

The right lung tissue of rats was fixed with 10% paraformaldehyde (Sigma-Aldrich; Merck KGaA) at room temperature for 48 h. Then the tissue was dehydrated in an ascending series of ethanol, embedded in paraffin and sectioned (5 µm). Following deparaffinization in xylene and rehydration in a descending series of alcohol, lung tissues were stained with H&E. Inflammatory cell infiltration and airway epithelial injury were observed under a light microscope.

 Masson staining

The aforementioned paraffin embedded slices (5 µm) were stained with Weigert solution (Sigma-Aldrich; Merck KGaA) for 5–10 min. After being fully washed, sections were treated with Ponceau fuchsin acid solution for 5–10 min, immersed in 2% acetic acid aqueous solution for 1 min, then differentiated in 1% phosphomolybdic acid aqueous solution for 3–5 min. Without washing with water, the sections were treated with aniline blue for 5 min then immersed in 0.2% acetic acid aqueous solution for 1 min. Slices were permeabilized with xylene and mounted with neutral resin.

 Measurement of the thicknesses of airway wall and smooth muscle

The intact small bronchioles were identified using a light microscope. Three transverse sections were randomly selected in each rat. Basement membrane perimeter (Pbm), total bronchial wall area (Wat1), bronchial luminal area (Wat2), external smooth muscle area (Wam1) and internal smooth muscle area (Wam2) of each rat were accessed using Image Pro Plus v.6.0 software (Media Cybernetics, Inc.). The thickness of airway wall (Wan) and smooth muscle (Wat) were then calculated using the following formulas:

(1) Wan=(Wat1-Wat2)/Pbm

(2) Wat=(Wam1-Wam2)/Pbm

 Determination of inflammatory factors in lung homogenate

Harvested rat lung tissue (0.5 g) was ground and centrifuged at 4,500 × g for 10 min at 4°C for preparation of lung homogenate. Levels of IL-1, IL-10, IL-12 and TNF-α in rat lung homogenate were detected using the respective ELISA kits (Rat IL-1 ELISA kit, cat. no. RAB0272; Rat IL-10 ELISA kit, cat. no. RAB0246; Rat TNF-α ELISA kit cat. no. RAB0480; all from Sigma-Aldrich; Merck KGaA; and Rat IL-12 ELISA kit, cat. no. KRC0121; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions.

Reverse transcription-quantitative PCR (RT-qPCR). The lung tissue (0.5 g) was cut and homogenized; TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA. Total RNA underwent reverse transcription according to the instructions of PrimeScript RT reagent Kit (Takara Bio, Inc.). qPCR was performed using SYBR®-Green Master Mix (Takara Bio, Inc.) according to the manufacturer's protocol; amplification was performed under the recommended parameters: Initial denaturation at 95°C for 5 min, followed by 40 cycles of 95°C for 5 sec, 60°C for 15 sec and 72°C for 15 sec, and a final extension at 94°C for 15 sec. The expression level of the target gene was calculated using the 2−ΔΔCq method (21). Primers are listed in Table I.

 Determination of inflammatory factors in serum of children

A total of 34 pediatric patients with asthma (age, 4–14 years; 19 male, 15 female), admitted to The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University (Changzhou, China) from January 2018 to May 2018 were selected as the asthma group. The diagnosis of childhood asthma conforms to the diagnostic criteria in the Guidelines for the Diagnosis and Prevention of Childhood Bronchial Asthma, formulated by the Respiratory Group of the Chinese Medical Association in 2008. Exclusion criteria: i) Patients with other tracheal, bronchial or pulmonary diseases; ii) patients with severe multiple organ, nervous or psychiatric diseases. Subjects were all in the acute asthmatic stage regardless of the severity of the attack. For the control group, 24 healthy children (age, 4–12 years; 13 male, 11 female) were selected during the same period. From each subject, 5 ml of venous blood sample was collected for detecting serum levels of IL-1, IL-10, IL-12 and TNF-α by ELISA. Written informed consent was obtained from the legal guardians for all patients and healthy controls.

 Statistical analysis

Data were analyzed by SPSS v.17.0 statistical software (SPSS Inc.). Quantitative data were presented as mean ± standard deviation. Student's t-test was used for comparing differences between two groups. One-way analysis of variance was performed for assessing differences amongst multiple groups, followed by Fisher's least significant difference analysis or Dunnett's test. P<0.05 was considered to indicate statistical significance.

 Results <sec> <title>High dose RES treatment attenuates pathological lesions in a rat asthma model

Pronounced pathological lesions were observed in the lung tissues of the asthma group, manifesting as edema and abscission of airway epithelium, airway constriction, multiple inflammatory cell infiltration and tracheal smooth muscle thickening (Fig. 1A). In addition, marked capillary congestion, alveolar fusion enlargement and alveolar septum widening were observed in asthma rats (Fig. 1A). Pathological changes were similar in the 10 µmol/l RES group. By contrast, pathological changes in lung tissues were less pronounced in the 50 µmol/l RES group compared with the asthma group (Fig. 1A).

 High dose RES treatment decreases airway collagen deposition area

Masson staining is commonly used to stain collagen fibers, mucus and cartilage blue. Muscle fibers, cellulose and red blood cells are stained red, whilst cell nuclei are stained blue-black. Airway collagen deposition was more marked in the asthma group compared with the sham group (Fig. 1B). No significant difference in airway collagen deposition area was observed between the asthma group and 10 µmol/l RES group (Fig. 1B). By contrast, the airway collagen deposition area was markedly reduced in the 50 µmol/l RES group compared with the asthma group (Fig. 1B).

 High dose RES treatment decreases inflammatory cell levels in the BALF of asthma model rats

Total amounts of inflammatory cells, eosinophils and lymphocytes were elevated in the asthma group and the 10 µmol/l RES group compared with the sham group (P<0.05; Fig. 2A-C). By contrast, the amounts of inflammatory cells, eosinophils and lymphocytes were significantly decreased in the 50 µmol/l RES group (P<0.05; Fig. 2A-C).

 High dose RES treatment decreases airway wall and smooth muscle thickness in asthma model rats

Airway wall and smooth muscle thickness were increased in the asthma group and 10 µmol/l RES group compared to the sham group (P<0.05; Fig. 2D and E). Treatment with 50 µmol/l RES decreased airway wall and smooth muscle thickness (P<0.05; Fig. 2D and E).

 High dose RES treatment decreases inflammatory factor levels in lung tissues of asthma model rats

ELISA results illustrated that IL-1, IL-10 and TNF-α levels in lung tissues of the asthma and 10 µmol/l RES groups were elevated, whereas IL-12 level was reduced (P<0.05; Fig. 3). In the 50 µmol/l RES group, IL-1, IL-10 and TNF-α levels were downregulated but IL-12 was upregulated in rat lung tissues following establishment of the asthma model (P<0.05; Fig. 3).

 High dose RES treatment reduces HMGB1, TLR4, MyD88 and NF-κB expression in asthma model rats

HMGB1, TLR4, MyD88 and NF-κB mRNA expression levels were remarkably elevated in rats of the asthma and 10 µmol/l RES groups compared with the sham group (P<0.05; Fig. 4). By contrast, 50 µmol/l RES treatment significantly decreased HMGB1, TLR4, MyD88 and NF-κB mRNA expression in rat lung tissue following establishment of the asthma model (P<0.05; Fig. 4).

 Inflammatory factor levels increase in serum samples of asthmatic children

Serum levels of IL-1, IL-10, IL-12 and TNF-α in asthma children and healthy children were analyzed. Asthmatic children had increased IL-1, IL-10 and TNF-α serum levels, as well as decreased IL-12 levels compared with healthy children (P<0.05; Fig. 5).

 Discussion

Bronchial asthma in children is a common disease that can severely influence daily life (1). Asthma can progress to adulthood if proper and timely treatment is not received. Pathologically, asthma is an airway chronic inflammatory disease involving a variety of cells and cellular components. Airway inflammation and remodeling are important pathological features of chronic asthma. IL-1β has an important role in the development of allergic asthma by inducing the formation of Th17 cells (22). IL-10 can regulate immune function and improve airway inflammatory response (23). IL-12 is a Th1 cytokine, which increases airway hyper responsiveness due to exogenous injury and decreases eosinophil aggregation around the airway (24). The present study determined that serum levels of IL-1, IL-10 and TNF-α in lung tissues of asthma model rats and serum samples of asthmatic children were significantly elevated. By contrast, IL-12 level was decreased. These results indicated that the inflammatory response is involved in the occurrence and progression of asthma.

HMGB1 is widely present in the cell nucleus and cytoplasm. Nuclear membrane permeability is increased by inflammation, which in turn promotes the translocation of HMGB1 to the cell cytoplasm where it exerts pro-inflammatory effects (14,25,26). HMGB1 stimulates mononuclear cell and macrophage-secreted inflammatory mediators, such as IL-1β, IL-10, IL-12 and TNF-α (27). In addition, HMGB1 promotes major histocompatibility complex II, CD80, CD83, CD86 and other costimulatory molecules in dendritic cells (DCs), inducing DC maturation to produce pro-inflammatory cytokines (28). Eosinophils are recruited by HMGB1 to the inflammatory sites further aggravating the inflammatory response (29,30). Recent studies have identified that HMGB2 deteriorates airway inflammation by upregulating TNF-α, VEGF, MMP-9 and TSLP expression. HMGB1 knockdown remarkably decreases relative indicators of airway inflammation, mucus secretion, collagen deposition, and airway smooth muscle thickness (31). TLR4 was the first TLR identified in mammals; it comprises an extracellular domain, a transmembrane domain and an intracellular domain (32,33). Relative studies have demonstrated that TLR4 is involved in the regulation of airway inflammation through regulating DC maturation and activation, antigen presentation and T cell immune responses. TLR4 is overexpressed in airway smooth muscle cells by elastase stimulation, leading to thickening of the airway wall via activation of NF-κB (34) therefore it is evident that TLR4 participates in airway remodeling. NF-κB is a nuclear transcription factor with various biological activities. NF-κB pathway regulates genes involved in asthma-related airway inflammation (35). Inhibition of NF-κB activity alleviates the airway inflammatory response, thereafter improving airway remodeling. TLR4 activates NF-κB through MyD88-dependent and MyD88-independent ways, eventually stimulating the production of pro-inflammatory factors. HMBG1 induces the immune and inflammatory response after binding to its receptor TLR4 (36,37). It is hypothesized that the HMGB1/TLR4/NF-κB pathway may serve an important role in the development and progression of asthma.

RES is a plant polyphenolic substance present in grape skins, berries and nuts (38). Numerous studies have demonstrated that RES exerts anti-apoptosis, anti-inflammatory and anti-oxidative effects in vitro (39–43). RES also alleviates airway inflammation and airway hyper responsiveness in vivo, partially through inhibiting eosinophil activation and degranulation (18,19). The most pronounced effect of RES is inflammation alleviation, mainly via NF-κB pathway regulation (44,45). RES is capable of inhibiting TLR4 expression in cardiomyocytes with hypoxia-reoxygenation injury (46). However, the pathogenesis of asthma and the mechanism of RES on asthma are complex. In the present study, airway lesions were obvious in asthma model rats, manifesting as abundant inflammatory cell infiltration. Pathological lesions in rat airways were remarkably alleviated by treatment with 50 µmol/l RES. However, 10 µmol/l RES treatment did not present therapeutic effect on asthma-induced inflammation. HMGB1, TLR4, MyD88 and NF-κB mRNA levels in 50 µmol/l RES group were significantly lower compared with the asthma group. Treatment with 10 µmol/l RES did not affect HMGB1, TLR4, MyD88 and NF-κB mRNA levels following establishment of an asthma model. The results confirmed that HMGB1 and TLR4 were involved in asthma-induced airway inflammation. However, the present study used only RT-qPCR to detect HMGB1, TLR4, MyD88 and NF-κB levels; additional experimental methods should be investigated in future work. In addition, detection of the remodeling-associated proteins and verification of which cell type is targeted by RES require to be further elucidated. Finally, the relationship of the HMGB1/TLR4/MyD88/NF-κB axis and RES will be further studied in future work.

In conclusion, the present study demonstrated that large dose RES alleviated asthma-induced airway inflammation and airway remodeling by inhibiting the release of inflammatory cytokines via the HMGB1/TLR4/NF-κB pathway. The present results provided evidence for RES as a potential novel treatment for asthma.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

HJ and WZ designed the study and performed the experiments. HJ, JD and KX established the animal models. HJ and KX collected the data. HJ and KX analyzed the data. HJ and WZ prepared the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Experimental protocols involving the use of animals were approved by the Animal Ethics Committee of Nanjing Medical University Animal Center. Protocols involving the use of human samples were approved by the Ethics Committee of the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University (Changzhou, China). Written informed consent was obtained from the legal guardians of all patients and healthy controls.

 Patient consent for publication

Not applicable.

 Competing interests

Not applicable.

 References GuilbertTWMaugerDTLemanskeRFJrChildhood asthma-predictive phenotypeJ Allergy Clin Immunol Pract2664670201410.1016/j.jaip.2014.09.01025439355 PinfieldJGaskinKBentleyJRouseJRecognition and management of asthma in children and young peopleNurs Stand305058201510.7748/ns.30.3.50.e998726373524 Us'KaVRRole of psychological factors in the etiology of asthma in childrenLik Sprava1481502015(In Ukrainian)26118055 CroisantSEpidemiology of asthma: Prevalence and burden of diseaseAdv Exp Med Biol7951729201410.1007/978-1-4614-8603-9_224162900 RaedlerDSchaubBImmune mechanisms and development of childhood asthmaLancet Respir Med2647656201410.1016/S2213-2600(14)70129-825008972 RosenbergSLMillerGEBrehmJMCeledonJCStress and asthma: Novel insights on genetic, epigenetic and immunologic mechanismsJ Allergy Clin Immunol13410091015201410.1016/j.jaci.2014.07.00525129683 KhanDAAllergic rhinitis and asthma: Epidemiology and common pathophysiologyAllergy Asthma Proc35357361201410.2500/aap.2014.35.379425295802 YangQLiuXYaoZMaoSWeiQChangYPenehyclidine hydrochloride inhibits the release of high-mobility group box 1 in lipopolysaccharide-activated RAW264.7 cells and cecal ligation and puncture-induced septic miceJ Surg Res186310317201410.1016/j.jss.2013.08.01524124976 MusumeciDRovielloGNMontesarchioDAn overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologiesPharmacol Ther141347357201410.1016/j.pharmthera.2013.11.00124220159 DumitriuIEBaruahPValentinisBVollREHerrmannMNawrothPPArnoldBBianchiMEManfrediAARovere-QueriniPRelease of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end productsJ Immunol17475067515200510.4049/jimmunol.174.12.750615944249 ParkJSSvetkauskaiteDHeQKimJYStrassheimDIshizakaAAbrahamEInvolvement of Τoll-like receptors 2 and 4 in cellular activation by high mobility group box 1 proteinJ Biol Chem27973707377200410.1074/jbc.M30679320014660645 YangHHreggvidsdottirHSPalmbladKWangHOchaniMLiJLuBChavanSRosas-BallinaMAl-AbedYA critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine releaseProc Natl Acad Sci USA1071194211947201010.1073/pnas.100389310720547845 AnderssonUWangHPalmbladKAvebergerACBloomOErlandsson-HarrisHJansonAKokkolaRZhangMYangHTraceyKJHigh mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytesJ Exp Med192565570200010.1084/jem.192.4.56510952726 ParkJSArcaroliJYumHKYangHWangHYangKYChoeKHStrassheimDPittsTMTraceyKJAbrahamEActivation of gene expression in human neutrophils by high mobility group box 1 proteinAm J Physiol Cell Physiol284C870C879200310.1152/ajpcell.00322.200212620891 WangJHeFChenLLiQJinSZhengHLinJZhangHMaSMeiJYuJResveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathwaysBiomed Pharmacother1053744201810.1016/j.biopha.2018.05.10429843043 WangXLLiTLiJHMiaoSYXiaoXZThe effects of resveratrol on inflammation and oxidative stress in a rat model of chronic obstructive pulmonary diseaseMolecules22E1529201710.3390/molecules2209152928895883 YangDLZhangHGXuYLGaoYHYangXJHaoXQLiXHResveratrol inhibits right ventricular hypertrophy induced by monocrotaline in ratsClin Exp Pharmacol Physiol37150155201010.1111/j.1440-1681.2009.05231.x19566840 OhYCKangOHChoiJGChaeHSLeeYSBriceOOJungHJHongSHLeeYMKwonDYAnti-inflammatory effect of resveratrol by inhibition of IL-8 production in LPS-induced THP-1 cellsAm J Chin Med3712031214200910.1142/S0192415X0900760019938227 TanYLimLHTrans-Resveratrol, an extract of red wine, inhibits human eosinophil activation and degranulationBr J Pharmacol1559951004200810.1038/bjp.2008.33018776917 ColittiMStefanonBDifferent anti-adipogenic effects of bio-compounds on primary visceral pre-adipocytes and adipocytesEXCLI J15362377201627540349 LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methodMethods25402408200110.1006/meth.2001.126211846609 EbenezerAJPrasadKRajanSThangamEBSilencing of H4R inhibits the production of IL-1β through SAPK/JNK signaling in human mast cellsJ Recept Signal Transduct Res38204212201810.1080/10799893.2018.146878329863427 ZhangYFengYLiLYeXWangJWangQLiPLiNZhengXGaoXImmunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthmaJ Mol Med (Berl)96249263201810.1007/s00109-017-1614-529302700 LinCLHsiaoGWangCCLeeYLImperatorin exerts antiallergic effects in Th2-mediated allergic asthma via induction of IL-10-producing regulatory T cells by modulating the function of dendritic cellsPharmacol Res110111121201610.1016/j.phrs.2016.04.03027185659 AbrahamEArcaroliJCarmodyAWangHTraceyKJHMG-1 as a mediator of acute lung inflammationJ Immunol16529502954200010.4049/jimmunol.165.6.295010975801 KimJYParkJSStrassheimDDouglasIDiaz del ValleFAsehnouneKMitraSKwakSHYamadaSMaruyamaIHMGB1 contributes to the development of acute lung injury after hemorrhageAm J Physiol Lung Cell Mol Physiol288L958L965200510.1152/ajplung.00359.200415640285 BauerEMShapiroRZhengHAhmadFIshizawarDComhairSAErzurumSCBilliarTRBauerPMHigh mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4Mol Med1815091518201310.2119/molmed.2012.0028323269975 DumitriuIEBianchiMEBacciMManfrediAARovere-QueriniPThe secretion of HMGB1 is required for the migration of maturing dendritic cellsJ Leukoc Biol818491200710.1189/jlb.030617117035340 MessmerDYangHTelusmaGKnollFLiJMessmerBTraceyKJChiorazziNHigh mobility group box protein 1: An endogenous signal for dendritic cell maturation and Th1 polarizationJ Immunol173307313200410.4049/jimmunol.173.1.30715210788 LotfiRHerzogGIDeMarcoRABeer-StolzDLeeJJRubartelliASchrezenmeierHLotzeMTEosinophils oxidize damage-associated molecular pattern molecules derived from stressed cellsJ Immunol18350235031200910.4049/jimmunol.090050419794066 LiangYHouCKongJWenHZhengXWuLHuangHChenYHMGB1 binding to receptor for advanced glycation end products enhances inflammatory responses of human bronchial epithelial cells by activating p38 MAPK and ERK1/2Mol Cell Biochem4056371201510.1007/s11010-015-2396-025862459 GranucciFZanoniIFeauSRicciardi-CastagnoliPDendritic cell regulation of immune responses: A new role for interleukin 2 at the intersection of innate and adaptive immunityEMBO J2225462551200310.1093/emboj/cdg26112773371 KawaiTAkiraSThe role of pattern-recognition receptors in innate immunity: Update on Toll-like receptorsNat Immunol11373384201010.1038/ni.186320404851 MacLeodHWetzlerLMT cell activation by TLRs: A role for TLRs in the adaptive immune responseSci STKE2007pe48200710.1126/stke.4022007pe4817785715 LeeKYHoSCLinHCLinSMLiuCYHuangCDWangCHChungKFKuoHPNeutrophil-derived elastase induces TGF-beta1 secretion in human airway smooth muscle via NF-kappaB pathwayAm J Respir Cell Mol Biol35407414200610.1165/rcmb.2006-0012OC16690986 MazaratiAMarosoMIoriVVezzaniACarliMHigh-mobility group box-1 impairs memory in mice through both Τoll-like receptor 4 and receptor for advanced Glycation end productsExp Neurol232143148201110.1016/j.expneurol.2011.08.01221884699 YuMWangHDingAGolenbockDTLatzECzuraCJFentonMJTraceyKJYangHHMGB1 signals through Τoll-like receptor (TLR) 4 and TLR2Shock26174179200610.1097/01.shk.0000225404.51320.8216878026 YadavMJainSBhardwajANagpalRPuniyaMTomarRSinghVParkashOPrasadGBMarottaFYadavHBiological and medicinal properties of grapes and their bioactive constituents: An updateJ Med Food12473484200910.1089/jmf.2008.009619627194 EoSHChoHKimSJResveratrol inhibits nitric oxide-induced apoptosis via the NF-kappa B pathway in rabbit articular chondrocytesBiomol Ther (Seoul)21364370201310.4062/biomolther.2013.02924244824 CsakiCKeshishzadehNFischerKShakibaeiMRegulation of inflammation signalling by resveratrol in human chondrocytes in vitroBiochem Pharmacol75677687200810.1016/j.bcp.2007.09.01417959154 ShakibaeiMJohnTSeifarthCMobasheriAResveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitroAnn NY Acad Sci1095554563200710.1196/annals.1397.06017404069 ElmaliNEsenkayaIHarmaAErtemKTurkozYMizrakBEffect of resveratrol in experimental osteoarthritis in rabbitsInflamm Res54158162200510.1007/s00011-004-1341-615883738 ImHJLiXChenDYanDKimJEllmanMBSteinGSColeBKcRCs-SzaboGvan WijnenAJBiological effects of the plant-derived polyphenol resveratrol in human articular cartilage and chondrosarcoma cellsJ Cell Physiol22734883497201210.1002/jcp.2404922252971 MannaSKMukhopadhyayAAggarwalBBResveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1 and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidationJ Immunol16465096519200010.4049/jimmunol.164.12.650910843709 EstrovZShishodiaSFaderlSHarrisDVanQKantarjianHMTalpazMAggarwalBBResveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cellsBlood102987995200310.1182/blood-2002-11-355012689943 ZhangCLinGWanWLiXZengBYangBHuangCResveratrol, a polyphenol phytoalexin, protects cardiomyocytes against anoxia/reoxygenation injury via the TLR4/NF-κB signaling pathwayInt J Mol Med29557563201210.3892/ijmm.2012.88522246136

Hematoxylin and eosin, and 2 of rat lung tissues demonstrating pathological lesions and collagen deposition following establishment of an asthma rat model. (A) Pathological lesions in rat lung tissue of sham, asthma, 10 µmol/l RES and 50 µmol/l RES groups. (B) Alterations of airway collage deposition (blue staining) in rat lung tissues of sham, asthma, 10 µmol/l RES and 50 µmol/l RES groups (magnification, ×200). RES, resveratrol.

Inflammatory cell amount in BALF, and airway wall and smooth muscle thickness for sham, asthma, 10 µmol/l RES and 50 µmol/l RES groups. (A) Number of inflammatory cells in rat BALF for different groups. (B) Number of eosinophils for different groups. (C) Number of lymphocytes for different groups. (D) Thickness of airway wall for different groups. (E) Thickness of airway smooth muscle for different groups. *P<0.05 vs. sham group; #P<0.05 vs. asthma group. BALF, bronchoalveolar lavage fluid; RES, resveratrol; EOS, eosinophils; LYM, lymphocytes; Wan, the thickness of airway wall; Wat, the thickness of smooth muscle.

IL-1, IL-10, IL-12 and TNF-α levels in rat lung tissues for sham, asthma, 10 µmol/l RES and 50 µmol/l RES groups. (A) IL-1β, (B) IL-10, (C) IL-12, and (D) TNF-α levels in rat lung tissues from the different experimental groups. *P<0.05 vs. control; #P<0.05 vs. asthma group. IL, interleukin; TNF-α, tumor necrosis factor-α; RES, resveratrol.

HMGB1, TLR4, MyD88 and NF-κB mRNA expression in rat lung tissues for sham, asthma, 10 µmol/l RES and 50 µmol/l RES groups. (A) HMGB1, (B) TLR4, (C) MyD88 and (D) NF-κB mRNA expression levels in rat lung tissues from the different experimental groups. *P<0.05 vs. control; #P<0.05 vs. asthma group. HMGB1, high mobility group box 1; TLR4, Τoll-like receptor; MyD88, myeloid differentiation primary response gene 88; RES, resveratrol.

Inflammatory factor levels in serum samples of asthmatic and healthy children. (A) Serum levels of IL-1β, (B) IL-10, (C) IL-12 and (D) TNF-α. *P<0.05 vs. control. IL, interleukin; TNF-α, tumor necrosis factor-α.

Primer sequences.

Gene name PCR size (bp) Primer sequence (5′→3′)
HMGB1 356 F:CGGATGCTTCTGTCAACT
R:TCAGCTTGGCAGCTTTCT
TLR4 310 F:GGTGAGAAATGAGCTGGTA
R:TCTGCTAAGAAGGCGATA
MyD88 113 F:CGTCGCATGGTGGTGGTTGTTT
R:GGGATCAGTCGCTTCTGTTGGA
NF-κB 425 F:GCGCATCCAGACCAACAATAAC
R:GCCGAAGCTGCATGGACACT
GAPDH 526 F:CCACTTGAAGGGTGGAGC
R:TGAAGTCGCAGGAGACAA

HMGB1, high mobility group box 1; MyD88, myeloid differentiation primary response gene 88; TLR4, Τoll-like receptor; R, reverse; F, forward.